As with other EGFRi, panitumumab did not improve progression-free survival over chemotherapy alone when used in metastatic TNBC.29 In contrast to these adjuvant trials in metastatic disease, use of panitumumab in combination with chemotherapy did appear efficacious as a neoadjuvant therapy for operable stage II–III TNBC.30 Overall, despite strong pre-clinical data linking high levels of EGFR to increased metastatic progression and decreased patient survival, TNBC in the metastatic setting appears to be unresponsive to EGFRi (Table 1). Here, EGFR is linked to metastatic neoplasm.